Richard A. Morgan
- Oncology top 0.2%
- Immunology top 0.5%
- Molecular Biology top 2%
- Genetics top 0.5%
- Biomedical Engineering top 5%
- Co-authors
- Steven A. RosenbergZhili ZhengNicholas P. RestifoSteven A. FeldmanYangbing ZhaoPaul F. RobbinsW. French AndersonMark E. Dudley
- Topics
- Virus-based gene therapy research (59 papers)CAR-T cell therapy research (59 papers)CRISPR and Genetic Engineering (21 papers)
- Cited by
- OncologyVirologyImmunology
- Journals
- Proceedings of the National Academy of SciencesJournal of the American Chemical SocietyAnnual Review of Biochemistry
- Partner nations
- United StatesUnited KingdomIsrael
In The Last Decade
Richard A. Morgan
110 papers receiving 7.3k citations
Hit Papers
Peers
Comparison fields: 5 of 130
- Oncology 4.8k
- Immunology 2.8k
- Molecular Biology 2.7k
- Genetics 2.5k
- Biomedical Engineering 877
Countries citing papers authored by Richard A. Morgan
This map shows the geographic impact of Richard A. Morgan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard A. Morgan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard A. Morgan more than expected).
Fields of papers citing papers by Richard A. Morgan
This network shows the impact of papers produced by Richard A. Morgan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard A. Morgan. The network helps show where Richard A. Morgan may publish in the future.
Co-authorship network of co-authors of Richard A. Morgan
This figure shows the co-authorship network connecting the top 25 collaborators of Richard A. Morgan. A scholar is included among the top collaborators of Richard A. Morgan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard A. Morgan. Richard A. Morgan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 11 | |
| 3 | 60 | |
| 4 | 4 | |
| 5 | 58 | |
| 6 | A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Responsebreakdown → | 585 |
| 7 | 11 | |
| 8 | 90 | |
| 9 | Revision to Australian standard AS4324.1-1995 for materials handling of bulk products | 1 |
| 10 | 41 | |
| 11 | 246 | |
| 12 | 94 | |
| 13 | 60 | |
| 14 | 64 | |
| 15 | EVAR for ruptured AAAs -- Do we need randomized controlled trials? | 1 |
| 16 | 164 | |
| 17 | 175 | |
| 18 | 1 | |
| 19 | 28 | |
| 20 | 89 |
About Richard A. Morgan
Richard A. Morgan is a scholar working on Oncology, Genetics and Virology, having authored 112 papers that have together received 7.4k indexed citations. Recurring topics across this work include Virus-based gene therapy research (59 papers), CAR-T cell therapy research (59 papers) and CRISPR and Genetic Engineering (21 papers). The work is most often cited by research in Oncology (4.8k citations), Virology (699 citations) and Immunology (2.8k citations). Richard A. Morgan has collaborated with scholars based in United States, United Kingdom and Israel. Frequent co-authors include Steven A. Rosenberg, Zhili Zheng, Nicholas P. Restifo, Steven A. Feldman, Yangbing Zhao, Paul F. Robbins, W. French Anderson, Mark E. Dudley, Barbara Ensoli and Robert C. Gallo. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Annual Review of Biochemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.